Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

in response to

Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024

KOO-KOO2

posted on Sep 25, 2024 02:08PM

It is surprising that Zenith is only going for an Equity Private Placement valued at $8M US.

Min subscription of $50K US to institutional and accredited investors.

The price per unit is 60 cents US with a 2-year warrant at 75 cents US.

As I understand it this adds 13.333 Million common shares to ZCC. The Proceeds for continuing oncology clinical development and for RVX apabatelone commercializing efforts.

Koo

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply